Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro

Journal of Steroid Biochemistry and Molecular Biology

Volumn 144, Issue PART A, 2014, Pages 50-58

  Deb, Subrata ^a   Chin, Mei Yieng ^a   Adomat, Hans ^a   Guns, Emma S Tomlinson ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Abiraterone; CYP3A4; Inhibition; Interaction; Microsomes

Indexed keywords

ABIRATERONE; CALCITRIOL; CYTOCHROME P450 3A4; KETOCONAZOLE; MIDAZOLAM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIAZOLAM;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTESTINE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; VITAMIN METABOLISM;

ABIRATERONE; CYP3A4; INHIBITION; INTERACTION; MICROSOMES; VITAMIN D(3);

ANDROSTENOLS; CYTOCHROME P-450 CYP3A; HUMANS; INTESTINES; LIVER; VITAMIN D;

EID: 84906789874     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.10.027     Document Type: Review

References (55)

1. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nat. Rev. Cancer 7 2007 684 700
2. S. Tretli, E. Hernes, J.P. Berg, U.E. Hestvik, and T.E. Robsahm Association between serum 25(OH)D and death from prostate cancer Br. J. Cancer 100 2009 450 454
3. D.L. Trump, M.K. Chadha, A.Y. Sunga, M.G. Fakih, U. Ashraf, C.G. Silliman, B.W. Hollis, M.K. Nesline, L. Tian, W. Tan, and C.S. Johnson Vitamin D deficiency and insufficiency among patients with prostate cancer BJU Int. 104 2009 909 914
4. T.C. Chen, and M.F. Holick Vitamin D and prostate cancer prevention and treatment Trends Endocr. Metab. 14 2003 423 430
5. T.M. Beer, C.W. Ryan, P.M. Venner, D.P. Petrylak, G.S. Chatta, J.D. Ruether, C.H. Redfern, L. Fehrenbacher, M.N. Saleh, D.M. Waterhouse, M.A. Carducci, D. Vicario, R. Dreicer, C.S. Higano, F.R. Ahmann, K.N. Chi, W.D. Henner, A. Arroyo, and F.W. Clow Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators J. Clin. Oncol. 25 2007 669 674
6. J.R. Muindi, Y. Peng, D.M. Potter, P.A. Hershberger, J.S. Tauch, M.J. Capozzoli, M.J. Egorin, C.S. Johnson, and D.L. Trump Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel Clin. Pharmacol. Ther. 72 2002 648 659
7. J.S. Chan, T.M. Beer, D.I. Quinn, J.K. Pinski, M. Garzotto, M. Sokoloff, D.R. Dehaze, and C.W. Ryan A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer BJU Int. 102 2008 1601 1606
8. G. Jones Extrarenal vitamin D activation and interactions between vitamin D, vitamin D, and vitamin D analogs Annu. Rev. Nutr. 33 2013 23 44
9. I. Schuster Cytochromes P450 are essential players in the vitamin D signaling system Biochim. Biophys. Acta 1814 2011 186 199
10. 3 in mouse and human liver: drug-related induction and inhibition of catabolism Drug Metab. Dispos. 40 2012 907 918
11. 3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia J. Bone Miner. Res. 28 2013 1101 1116
12. K.E. Thummel, and G.R. Wilkinson In vitro and in vivo drug interactions involving human CYP3A Annu. Rev. Pharmacol. Toxicol. 38 1998 389 430
13. S.F. Zhou Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 Curr. Drug Metab. 9 2008 310 322
14. R.D. Beckett, K.M. Rodeffer, and R. Snodgrass Abiraterone for the treatment of metastatic castrate-resistant prostate cancer Ann. Pharmacother. 46 2012 1016 1024
15. K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, K.N. Chi, R.J. Jones, J.N. Staffurth, S. North, N.J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O.B. Goodman Jr., C.N. Sternberg, J.H. Li, T. Kheoh, C.M. Haqq, and J.S. de Bono Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol. 13 2012 983 992
16. D.J. Bedoya, and N. Mitsiades Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions Onco. Targets Ther. 6 2013 9 18
17. T. Goldberg, and E. Berrios-Colon Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer P T 38 2013 23 26
18. C.J. Logothetis, E. Basch, A. Molina, K. Fizazi, S.A. North, K.N. Chi, R.J. Jones, O.B. Goodman, P.N. Mainwaring, C.N. Sternberg, E. Efstathiou, D.D. Gagnon, M. Rothman, Y. Hao, C.S. Liu, T.S. Kheoh, C.M. Haqq, H.I. Scher, and J.S. de Bono Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol. 13 2012 1210 1217
19. M. Chiba, L. Jin, W. Neway, J.P. Vacca, J.R. Tata, K. Chapman, and J.H. Lin P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra Drug Metab. Dispos. 29 2001 1 3
20. A.M. Filppula, J. Laitila, P.J. Neuvonen, and J.T. Backman Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates Br. J. Pharmacol. 165 2012 2787 2798
21. C. Gaudineau, and K. Auclair Inhibition of human P450 enzymes by nicotinic acid and nicotinamide Biochem. Biophys. Res. Commun. 317 2004 950 956
22. E.S. Perloff, A.K. Mason, S.S. Dehal, A.P. Blanchard, L. Morgan, T. Ho, A. Dandeneau, R.M. Crocker, C.M. Chandler, N. Boily, C.L. Crespi, and D.M. Stresser Validation of cytochrome P450 time-dependent inhibition assays: A two-time point IC50 shift approach facilitates kinact assay design Xenobiotica 39 2009 99 112
23. J.Y. Wang, S. Swami, A.V. Krishnan, and D. Feldman Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer Prostate 72 2012 1628 1637
24. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, R. Horst, M.A. Albertelli, and D. Feldman Dietary vitamin D(3) and 1, 25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer Endocrinology 153 2012 2576 2587
25. 3 in the rat Am. J. Physiol. 248 1985 G718 G725
26. M.R. Haussler, P.W. Jurutka, M. Mizwicki, and A.W. Norman Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms Best Pract. Res. Clin. Endocrinol. Metab. 25 2011 543 559
27. Y. Xu, T. Hashizume, M.C. Shuhart, C.L. Davis, W.L. Nelson, T. Sakaki, T.F. Kalhorn, P.B. Watkins, E.G. Schuetz, and K.E. Thummel Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia Mol. Pharmacol. 69 2006 56 65
28. R.P. Gupta, B.W. Hollis, S.B. Patel, K.S. Patrick, and N.H. Bell CYP3A4 is a human microsomal vitamin D 25-hydroxylase J. Bone Miner. Res. 19 2004 680 688
29. N. Urushino, K. Yasuda, S. Ikushiro, M. Kamakura, M. Ohta, and T. Sakaki Metabolism of 1alpha,25-dihydroxyvitamin D2 by human CYP24A1 Biochem. Biophys. Res. Commun. 384 2009 144 148
30. S.A. Kliewer, B. Goodwin, and T.M. Willson The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism Endocr. Rev. 23 2002 687 702
31. E.D. Crawford, R. Grubb 3rd., A. Black, G.L. Andriole Jr., M.H. Chen, G. Izmirlian, C.D. Berg, and A.V. D'Amico Comorbidity and mortality results from a randomized prostate cancer screening trial J. Clin. Oncol. 29 2011 355 361
32. P.N. Post, P.J. Kil, A.J. Hendrikx, M.L. Janssen-Heijnen, M.A. Crommelin, and J.W. Coebergh Comorbidity in patients with prostate cancer and its relevance to treatment choice BJU Int. 84 1999 652 656
33. M. Shou, M. Hayashi, Y. Pan, Y. Xu, K. Morrissey, L. Xu, and G.L. Skiles Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction Drug Metab. Dispos. 36 2008 2355 2370
34. K.N. Chi, A. Tolcher, P. Lee, P.J. Rosen, C.K. Kollmannsberger, K.P. Papadopoulos, A. Patnaik, A. Molina, J. Jiao, C. Pankras, B. Kaiser, A. Bernard, N. Tran, and M. Acharya Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer Cancer Chemother. Pharmacol. 71 2013 237 244
35. D.E. Prosser, and G. Jones Enzymes involved in the activation and inactivation of vitamin D Trends Biochem. Sci. 29 2004 664 673
36. J.B. Cheng, D.L. Motola, D.J. Mangelsdorf, and D.W. Russell De-orphanization of cytochrome P450 2R1: A microsomal vitamin D 25-hydroxilase J. Biol. Chem. 278 2003 38084 38093
37. 3, and vitamin d analogs Annu. Rev. Nutr. 33 2013 23 44
38. I. Schuster, N. Astecker, H. Egger, G. Herzig, G.S. Reddy, M. Schuessler, G. Vorisek, and Ch. Wachter Inhibitors of vitamin D hydroxylases: mechanistic tools and therapeutic aspects V.D. Stolzt, New Topics in Vitamin D Research 2006 Nova Science Publishers 1-60021-001-5 67 144
39. D.S. Rao, M.J. Campbell, H.P. Koeffler, S. Ishizuka, M.R. Uskokovic, P. Spagnuolo, and G.S. Reddy Metabolism of 1alpha,25-dihydroxyvitamin D(3) in human promyelocytic leukemia (HL-60) cells: in vitro biological activities of the natural metabolites of 1alpha,25-dihydroxyvitamin D(3) produced in HL-60 cells Steroids 66 2001 423 431
40. J.A. Agundez, C. Martinez, M. Olivera, L. Gallardo, J.M. Ladero, C. Rosado, J. Prados, J. Rodriguez-Molina, L. Resel, and J. Benitez Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk Br. J. Cancer 78 1998 1361 1367
41. O.A. Di Paolo, C.H. Teitel, S. Nowell, B.F. Coles, and F.F. Kadlubar Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways Int. J. Cancer 117 2005 8 13
42. W. Zhang, W.D. Shannon, J. Duncan, G.L. Scheffer, R.J. Scheper, and H.L. McLeod Expression of drug pathway proteins is independent of tumour type J. Pathol. 209 2006 213 219
43. R. Obligacion, M. Murray, and I. Ramzan Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition J. Androl. 27 2006 138 150
44. 3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients J. Clin. Endocrinol. Metab. 98 2013 1498 1507
45. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, F. Raynaud, V. Martins, G. Lee, T. Kheoh, J. Kim, A. Molina, and E.J. Small Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J. Clin. Oncol. 28 2010 1481 1488
46. U.S. FDA Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Draft Guidance 2012 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf (last accessed 01.08.13)
47. J.R. Muindi, W.D. Yu, Y. Ma, K.L. Engler, R.X. Kong, D.L. Trump, and C.S. Johnson CYP24A1 inhibition enhances the antitumor activity of calcitriol Endocrinology 151 2010 4301 4312
48. W. Luo, P.A. Hershberger, D.L. Trump, and C.S. Johnson 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics J. Steroid Biochem. Mol. Biol. 136 2013 252 257
49. U. Querfeld, and R.H. Mak Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window Pediatr. Nephrol. 25 2010 2413 2430
50. G. Garg, R. Khadgwat, D. Khandelwal, and N. Gupta Vitamin D toxicity presenting as hypercalcemia and complete heart block: an interesting case report Indian J. Endocrinol. Metab. 16 2012 S423 S425
51. G. Jones Pharmacokinetics of vitamin D toxicity Am. J. Clin. Nutr. 88 2008 582S 586S
52. J.J. Hsu, Y. Tintut, and L.L. Demer Vitamin D and osteogenic differentiation in the artery wall Clin. J. Am. Soc. Nephrol. 3 2008 1542 1547
53. M.J. McKenna, and B.F. Murray Vitamin D dose response is underestimated by Endocrine Society's Clinical Practice Guideline Endocr. Connect. 2 2013 87 95
54. A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, and S.A. Shapses The 2011 dietary reference intakes for calcium and vitamin D: what dietetics practitioners need to know J. Am. Diet. Assoc. 111 2011 524 527
55. T.M. Beer, M. Javle, G.N. Lam, W.D. Henner, A. Wong, and D.L. Trump Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer Clin. Cancer Res. 11 2005 7794 7799